Table 2 The association of B7-H4 and p-PKCδ with clinical parameters
Variables | B7-H4 (%) | p-PKCδ (%) | p-PKCδ+B7-H4+ (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|
Positive (n = 132) | Negative (n = 93) | P valuea | Positive (n = 139) | Negative (n = 86) | P valuea | Positive (n = 101) | Others (n = 124) | P valuea | |
Gender | |||||||||
Male (n = 122) | 72 (59.0%) | 50 (41.0%) | 0.908 | 78 (63.9%) | 44 (36.1%) | 0.469 | 53 (43.4%) | 69 (56.6%) | 0.635 |
Female (n = 103) | 60 (58.3%) | 43 (41.7%) | 61 (59.2%) | 42 (40.8%) | 48 (46.6%) | 55 (53.4%) | |||
Histology | |||||||||
Well (n = 36) | 13 (36.1%) | 23 (63.9%) | 0.003b | 22 (61.1%) | 14 (38.9%) | 0.928 | 10 (27.8%) | 26 (72.2%) | 0.024b |
Moderate/poor (n = 189) | 119 (63.0%) | 70 (37.0%) | 117 (61.9%) | 72 (38.1%) | 91 (48.1%) | 98 (51.9%) | |||
Depth of tumor | |||||||||
T1 + T2 (n = 51) | 26 (51%) | 25 (49%) | 0.205 | 31 (52.6%) | 20 (47.4%) | 0.868 | 19 (15.8%) | 32 (84.2%) | 0.213 |
T3 + T4 (n = 174) | 106 (60.9%) | 68 (39.1%) | 108 (69.1%) | 66 (30.9%) | 82 (47.1%) | 92 (52.9%) | |||
Lymph node metastasis | |||||||||
Negative (n = 136) | 69 (50.7%) | 67 (49.3%) | 0.003b | 79 (58.1%) | 57 (41.9%) | 0.159 | 49 (36.0%) | 87 (64.0%) | 0.001b |
Positive (n = 89) | 63 (70.8%) | 26 (29.2%) | 60 (67.4%) | 29 (32.6%) | 52 (58.4%) | 37 (41.6%) | |||
Dukes’ stage | |||||||||
A + B (n = 122) | 63 (51.6%) | 59 (48.4%) | 0.020b | 68 (55.7%) | 54 (44.3%) | 0.042b | 43 (35.2%) | 79 (64.8%) | 0.002b |
C + D (n = 103) | 69 (67.0%) | 34 (33.0%) | 71 (68.9%) | 32 (31.1%) | 58 (56.3%) | 45 (43.7%) | |||